Posted inHematology-Oncology news Oncology
Immune Checkpoint Inhibitor Rechallenge in Classical Hodgkin Lymphoma: Efficacy and Safety Insights from an Off-Trial Cohort
This study evaluates the safety and clinical outcomes of immune checkpoint inhibitor rechallenge in classical Hodgkin lymphoma patients following immune-related adverse events, demonstrating feasibility and preserved efficacy in selected cases.